Histiocytic sarcoma in the brain of a cat.
A mass lesion in the subependymal region of the lateral ventricle in a 13-year-old neutered male mongrel cat with a complaint of somnolence, right circling movement and posture abnormality was examined. The magnetic resonance image examination revealed a relatively large T1-hypointense and T2-hyperintense mass lesion in the left interventricular foramen region, and there were no abnormalities in the chest and abdominal x-ray radiographic, funduscopic, and electric retinogram findings. The cat was died 43 days after the initial referral, and the post-mortem examinations revealed a poorly demarcated subependymal mass. Histologically, the brain lesion consisted of complex proliferation of highly pleomorphic cells resembling histiocytes with atypia and abundant mitotic figures. Moderate infiltrates of small reactive lymphocytes were admixed with the pleomorphic cell population. Gemistcytic astrocytes were also intermingled with the periphery of neoplastic foci. Immunohistochemically, most of the pleomorphic cells were positive for HLA-DR alpha-chain and ionized calcium binding adaptor molecule 1, and few were positive for lysozyme and alpha-1 antichymotrypsin. The atypical pleomorphic cells were negative for CD3, IgG (H and L), glial fibrillary acidic protein and neurofilament, suggesting monocytic/histiocytic-origin of the cells. The number of Ki-67-positive cell nuclei was extremely large, reflecting the high growth activity of these cells. Based on the findings, the lesion was considered as histiocytic sarcoma.
Ide
Tetsuya
T
Department of Veterinary Pathology, Graduate School of Agricultural and Life Science, The University of Tokyo, Toyko, Japan. aa087111@mail.ecc.u-tokyo.ac.jp
Uchida
Kazuyuki
K
Tamura
Shinji
S
Nakayama
Hiroyuki
H
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000473:pathology / Q000662:veterinary*; D002371:Cat Diseases / Q000473:pathology*; D002415:Cats; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D054747:Histiocytic Sarcoma / Q000473:pathology / Q000662:veterinary*; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D004317:Doxorubicin; D011239:Prednisolone